Conventional ADCs composing of IgG suffer from issues such as poor tissue permeability and suboptimal efficacy, attributed to their large volume and poor homogeneity. While the utilization of novel recombinant antibody formats as drug conjugates offers a promising approach for more precise cancer targeting. One significant advantage of these recombinant antibody formats is their smaller size, which allows for optimal penetration into solid tumors. This characteristic enables them to reach deep-seated tumor cells that may be difficult to target with conventional therapies. Moreover, these novel format ADCs have different pharmacokinetics from conventional ADCs, manifested by faster peaking and clearance. Last, recombinant antibody formats possess enhanced physical and chemical properties, rendering their drug conjugates conferring favorable characteristics.